{
    "2020-03-08": [
        [
            {
                "time": "",
                "original_text": "【药咖君】恒瑞创新药强劲发力，卡瑞利珠单抗肝癌适应症获批；瓜分全球$70亿蛋糕，利伐沙班又一企业入局；武田制药",
                "features": {
                    "keywords": [
                        "恒瑞",
                        "创新药",
                        "卡瑞利珠单抗",
                        "肝癌适应症",
                        "利伐沙班",
                        "武田制药"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}